Profile and potential of ixabepilone in the treatment of pancreatic cancer

References

• Sener SF Fremgen A Menck HR Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database J Am Coll Surg 1999 189 1 1 7 10401733
   PubMed Web of Science ®Google Scholar
• Geer RJ Brennan MF Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 1993 165 1 68 72 8380315
   PubMed Web of Science ®Google Scholar
• seer.cancer.gov [homepage on the Internet] Bethesda, MD, USA National Cancer Institute Available from: http://seer.cancer.gov/statfacts/html/pancreas.html Accessed July 9, 2013
   Google Scholar
• Stanton RA Gernert KM Nettles JH Aneja R Drugs that target dynamic microtubules: a new molecular perspective Med Res Rev 2011 31 3 443 481 21381049
   PubMed Web of Science ®Google Scholar
• Goodin S Novel cytotoxic agents: epothilones Am J Health Sys Pharm 2008 65 10 s10 s15
   Web of Science ®Google Scholar
• Jordan A Hadfield JA Lawrence NJ McGown AT Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle Med Res Rev 1998 18 4 259 296 9664292
   PubMed Web of Science ®Google Scholar
• Abu-Khalaf MM Harris LN Antimicrotubule agents DeVita VT Lawrence TS Rosenberg SA DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology 9th ed Philadelphia, PA, USA Lippincott, Williams and Wilkins 2011
   Google Scholar
• Morris PG Fornier MN Microtubule active agents: beyond the taxane frontier Clin Cancer Res 2008 14 22 7167 7172 19010832
   PubMed Web of Science ®Google Scholar
• Fumoleau P Coudert B Isambert N Ferrant E Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues Ann Oncol 2007 18 Suppl 5 v9 v15 17656562
   PubMed Web of Science ®Google Scholar
• Giannakakou P Gussio R Nogales E A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cells Proc Natl Acad Sci U S A 2000 97 6 2904 2909 10688884
   PubMed Web of Science ®Google Scholar
• Bollag DM McQueeney PA Zhu J Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 1995 55 11 2325 2333 7757983
   PubMed Web of Science ®Google Scholar
• Lee FY Borzilleri R Fairchild CR BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 2001 7 5 1429 1437 11350914
   PubMed Web of Science ®Google Scholar
• Kowalski RJ Giannakakou P Hamel E Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel J Biol Chem 1997 272 4 2534 2541 8999970
   PubMed Web of Science ®Google Scholar
• Von Hoff DD Ervin TJ Arena FP Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) J Clin Oncol 2012 30 Suppl 34 LBA148
   Google Scholar
• Dakik HK Moskovic DJ Carlson PJ The use of GTX as a second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis Cancer Chemother Pharmacol 2012 69 2 425 430 21850466
   PubMed Web of Science ®Google Scholar
• De Jesus-Acosta A Oliver GR Blackford A A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma Cancer Chemother Pharmacol 2012 69 2 415 424 21800112
   PubMed Web of Science ®Google Scholar
• Rivera E Lee J Davies A Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors Oncologist 2008 13 12 1207 1223 19088324
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration FDA approves Ixempra for advanced breast cancer patients Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109015.htm Accessed July 31, 2013
   Google Scholar
• Awada A Piccart M Jones SF Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy Cancer Chemother Pharmacol 2009 63 3 417 425 18446338
   PubMed Web of Science ®Google Scholar
• Shimizu T Yamamoto N Yamada Y Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone, an epothilone B analog, in Japanese patients with refractory solid tumors Cancer Chemother Pharmacol 2008 61 5 751 758 17594093
   PubMed Web of Science ®Google Scholar
• He AR Kunz PL Pishvaian MJ A phase I study of an oral formulation of ixabepilone in patients with advanced cancer J Clin Oncol 2010 28 Suppl 15 e13090
   Web of Science ®Google Scholar
• Kunz PL He AR Colevas AD Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors Invest New Drugs 2012 30 6 2364 2370 22331549
   PubMed Web of Science ®Google Scholar
• Whitehead RP McCoy S Rivkin SE A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a southwest oncology group study Invest New Drugs 2006 24 6 515 520 16699973
   PubMed Web of Science ®Google Scholar
• Whitehead RP Jacobson J Brown TD Taylor SA Weiss GR Macdonald JS Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study J Clin Oncol 1997 15 6 2414 2419 9196157
   PubMed Web of Science ®Google Scholar
• Burris HA Moore MJ Andersen J Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 1997 15 6 2403 2413 9196156
   PubMed Web of Science ®Google Scholar
• Faivre S Delbaldo C Boige V Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies Eur J Cancer 2008 44 5 674 682 18308561
   PubMed Web of Science ®Google Scholar
• Plummer R Woll P Fyfe D A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies Clin Cancer Res 2008 14 24 8288 8294 19088046
   PubMed Web of Science ®Google Scholar
• Kittaneh M Montero AJ Kovacs K Phase I trial of weekly and every 3 weeks ixabepilone and sunitinib in advanced solid tumors J Clin Oncol 2011 29 Suppl 15 3081
   Web of Science ®Google Scholar
• Herbolsheimer P Kapoor R Smith KL Phase I trial of dasatinib and ixabepilone in patients with solid tumors Invest New Drugs 2013 31 1 92 98 22392508
   PubMed Web of Science ®Google Scholar
• Sprycel [package insert] Princeton, NJ, USA Bristol-Myers Squibb Company 2013
   Google Scholar
• Rocha Lima CM Lin EH Kim GP A phase 2 trial of ixabepilone plus cetuximab in first line-treatment of metastatic pancreatic cancer Gastrointest Cancer Res 2012 5 5 155 160 23112883
   PubMedGoogle Scholar
• Conroy T Desseigne F Ychou M FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 2011 364 19 1817 1825 21561347
   PubMed Web of Science ®Google Scholar